Medicure Inc
- LAST PRICE0.8800
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.8800/ 57
- Ask / Lots0.9900/ 4
- Open / Previous Close--- / 0.8800
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
Nov 18, 2024
Oct 24, 2024
Medicure Announces Positive Settlement of Product Development and Supply Contracts, from 6:01PM ET on Thursday Oct 24, 2024 by Dow Jones
6:01PM ET on Thursday Oct 24, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Medicure Inc | 9.2M | -3.5x | --- |
Numinus Wellness Inc | 16.1M | -0.6x | --- |
Avicanna Inc | 29.0M | -3.7x | --- |
Microbix Biosystems Inc | 40.7M | 8.1x | --- |
StageZero Life Sciences Ltd | 4.9M | 0.0x | --- |
COSCIENS Biopharma Inc | 15.0M | -0.4x | --- |
Company Information
Medicure Inc. is a pharmaceutical company. It is focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market. The focus of it is the marketing and distribution of AGGRASTAT (tirofiban hydrochloride) injection and ZYPITAMAG (pitavastatin) tablets in the United States, where they are sold through the Company's United States subsidiary, Medicure Pharma Inc. It also operates Marley Drug Inc. (Marley Drug), a pharmacy subsidiary servicing all 50 states, Washington D.C. and Puerto Rico. Marley Drug is committed to improving access to medication for all Americans together with exceptional customer service and free home delivery. AGGRASTAT is indicated to reduce the rate of thrombotic cardiovascular events in patients with non-ST elevation acute coronary syndrome. It also develops pyridoxal 5'-phosphate analogues (P5P Analogues), the processes for their preparation, compositions containing P5P Analogues.
Contact Information
- Headquarters
- 1250 Waverley StreetWINNIPEG, MB, Canada R3T 6C6
- Phone
- 204-487-7412
- Fax
- 204-487-7412
Executives
- Chairman of the Board, Chief Executive Officer
- Albert Friesen
- President, Chief Operating Officer
- Neil Owens
- Chief Financial Officer
- Haaris Uddin
- Director
- James Kinley
- Independent Director
- Brent Fawkes
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $9.2M |
|---|---|
Revenue (TTM) | $20.9M |
Shares Outstanding | 10.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.78 |
EPS | $-0.25 |
Book Value | $1.91 |
P/E Ratio | -3.5x |
Price/Sales (TTM) | 0.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -12.35% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
